4-methyl-2-pyridin-3-yl-thiazole-5-carboxylic acid [2-(3[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide | 1093403-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-2-pyridin-3-yl-thiazole-5-carboxylic acid [2-(3[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide
• 英文别名: 4-methyl-2-pyridin-3-yl-N-[2-[3-(1,2,4-triazol-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-1,3-thiazole-5-carboxamide
• CAS: 1093403-43-0
• 化学式: C₂₄H₁₈N₈OS₂
• 分子量: 498.592
• InChiKey: UUCNOHOLAGNGBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  159
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-溴-2′-硝基苯乙酮 在 palladium 10% on activated carbon 、 N,N-二甲基甲酰胺 、 sodium iodide N-甲基吗啉 、 sodium hydroxide 、 氯化亚砜 、 水 、 氢气 、 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 89.75h， 生成 4-methyl-2-pyridin-3-yl-thiazole-5-carboxylic acid [2-(3[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide
  参考文献：
  名称：

  WO2008/156866

  摘要：

  公开号：

文献信息

• The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate
  作者：Pui Ng、Jean Bemis、Jeremy Disch、Chi Vu、Christopher Oalmann、Amy Lynch、David Carney、Thomas Riera、Jeffrey Song、Jesse Smith、Siva Lavu、Angela Tornblom、Meghan Duncan、Marie Yeager、Kristina Kriksciukaite、Akanksha Gupta、Vipin Suri、Peter Elliot、Jill Milne、Joseph Nunes、Michael Jirousek、George Vlasuk、James Ellis、Robert Perni

  DOI：10.2174/15701808113100990021

  日期：2013.9.1

  We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting.

  我们发现 SRT2104 (4) 是首个直接合成的 SIRT1 激活剂临床候选药物。该化合物是通过优化之前描述的咪唑并[1,2-b]噻唑支架而得到的。SRT2104 是基于生化活性和药代动力学特征的综合考虑而被选为候选开发药物的。SRT2104 的体内特性优于具有类似活化特征的类似物。整体临床前研究结果表明，该化合物具有在临床环境中提供治疗益处的潜力。
• Sirtuin modulating compounds
  申请人：Bemis Jean

  公开号：US20090012080A1

  公开（公告）日：2009-01-08

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块疾病，炎症，癌症和/或潮红，以及受益于增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一种治疗剂的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Bemis Jean

  公开号：US20110015192A1

  公开（公告）日：2011-01-20

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的调节sirtuin的化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗/预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。此外，还提供了包含sirtuin调节化合物与另一种治疗剂的组合物。
• SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS
  申请人：GlaxoSmithKline LLC

  公开号：EP2167510B1

  公开（公告）日：2015-02-25
• Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response
  申请人：VERDIN ERIC M.

  公开号：US20100330114A1

  公开（公告）日：2010-12-30

  The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4 + T cells.